来自血液和骨髓移植临床研究网络骨髓瘤协作组关于多发性骨髓瘤免疫和细胞治疗的研讨会会议记录。
Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
机构信息
University of Nebraska Medical Center, Omaha, Nebraska.
Moores Cancer Center, University of California San Diego, La Jolla, California.
出版信息
Transplant Cell Ther. 2022 Aug;28(8):446-454. doi: 10.1016/j.jtct.2022.05.019. Epub 2022 May 21.
Abstract
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup conducted a workshop on Immune and Cellular Therapy in Multiple Myeloma on January 7, 2022. This workshop included presentations by basic, translational, and clinical researchers with expertise in plasma cell dyscrasias. Four main topics were discussed: platforms for myeloma disease evaluation, insights into pathophysiology, therapeutic target and resistance mechanisms, and cellular therapy for multiple myeloma. Here we provide a comprehensive summary of these workshop presentations.
摘要
血液和骨髓移植临床研究网络（BMT CTN）骨髓瘤协作组于 2022 年 1 月 7 日举办了多发性骨髓瘤免疫和细胞治疗研讨会。本次研讨会由基础、转化和临床研究人员进行了专题报告，他们在浆细胞疾病方面具有专业知识。主要讨论了四个主题：骨髓瘤疾病评估平台、发病机制见解、治疗靶点和耐药机制以及多发性骨髓瘤的细胞治疗。在这里，我们对这些研讨会的报告进行了全面总结。
相似文献
1
Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
Transplant Cell Ther. 2022 Aug;28(8):446-454. doi: 10.1016/j.jtct.2022.05.019. Epub 2022 May 21.
2
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant. 2020 Oct;26(10):e247-e255. doi: 10.1016/j.bbmt.2020.06.011. Epub 2020 Jun 24.
3
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
Transplant Cell Ther. 2021 Oct;27(10):807-816. doi: 10.1016/j.jtct.2021.05.027. Epub 2021 Jun 6.
4
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant. 2020 Jan;26(1):e7-e15. doi: 10.1016/j.bbmt.2019.09.015. Epub 2019 Sep 14.
5
BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.
Biol Blood Marrow Transplant. 2018 Apr;24(4):641-648. doi: 10.1016/j.bbmt.2017.12.774. Epub 2017 Dec 11.
6
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant. 2019 Mar;25(3):e89-e97. doi: 10.1016/j.bbmt.2018.11.001. Epub 2018 Nov 5.
7
Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Curr Cancer Drug Targets. 2017;17(9):782-805. doi: 10.2174/1568009617666170214103834.
8
Role of the bone marrow microenvironment in multiple myeloma treatment using CAR-T therapy.
Expert Rev Anticancer Ther. 2023 Jul-Dec;23(8):807-815. doi: 10.1080/14737140.2023.2229029. Epub 2023 Jun 27.
9
Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Pharmacotherapy. 2017 Jan;37(1):129-143. doi: 10.1002/phar.1871. Epub 2017 Jan 6.
10
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30.
本文引用的文献
1
Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival.
Sci Rep. 2022 Jan 7;12(1):30. doi: 10.1038/s41598-021-03748-0.
2
Redefining nonmeasurable multiple myeloma using mass spectrometry.
Blood. 2022 Feb 10;139(6):946-950. doi: 10.1182/blood.2021013794.
3
Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma.
Blood Cancer Discov. 2020 Aug 3;1(2):130-133. doi: 10.1158/2643-3230.BCD-20-0122. eCollection 2020 Sep.
4
In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [F]FDG and [Cu]Cu-LLP2A PET.
EJNMMI Res. 2021 Sep 29;11(1):97. doi: 10.1186/s13550-021-00840-4.
5
Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM.
Blood Adv. 2021 Oct 12;5(19):3794-3798. doi: 10.1182/bloodadvances.2021004418.
6
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma.
Nat Commun. 2021 Aug 27;12(1):5172. doi: 10.1038/s41467-021-25469-8.
7
Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.
Blood Cancer Discov. 2021 Jul;2(4):354-369. doi: 10.1158/2643-3230.BCD-21-0038.
8
Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells.
STAR Protoc. 2021 May 27;2(2):100565. doi: 10.1016/j.xpro.2021.100565. eCollection 2021 Jun 18.
9
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
Transplant Cell Ther. 2021 Oct;27(10):807-816. doi: 10.1016/j.jtct.2021.05.027. Epub 2021 Jun 6.
10
Understanding the Mechanisms of Resistance to T Cell-based Immunotherapies to Develop More Favorable Strategies in Multiple Myeloma.
Hemasphere. 2021 Jun 1;5(6):e575. doi: 10.1097/HS9.0000000000000575. eCollection 2021 Jun.
Zotero 插件